Get the Stockscreener App
151.12
3.30%
-5.15
After Hours:
151.50
0.38
+0.25%
Novartis Ag Adr stock is traded at $151.12, with a volume of 4.36M.
It is down -3.30% in the last 24 hours and up +5.89% over the past month.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
See More
Previous Close:
$156.27
Open:
$156.08
24h Volume:
4.36M
Relative Volume:
2.28
Market Cap:
$287.24B
Revenue:
$54.66B
Net Income/Loss:
$13.58B
P/E Ratio:
21.54
EPS:
7.0171
Net Cash Flow:
$16.05B
1W Performance:
+0.33%
1M Performance:
+5.89%
6M Performance:
+2.47%
1Y Performance:
+14.80%
1-Day Range:
$149.17
$156.08
1-Week Range:
$149.17
$157.10
52-Week Range:
$121.57
$170.46
Novartis Ag Adr Stock (NVS) Company Profile
Name
Novartis Ag Adr
Sector
Industry
Phone
-
Address
-
Compare NVS vs LLY, JNJ, ABBV, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
151.12 | 287.24B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,273.46 | 1.14T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.81 | 635.07B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
285.64 | 504.76B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.27 | 358.41B | 65.51B | 8.93B | 14.12B | 3.5532 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-26 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-09-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-09-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-11-26 | Upgrade | Argus | Hold → Buy |
| Jan-27-26 | Initiated | Citigroup | Buy |
| Jan-06-26 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-12-25 | Downgrade | Goldman | Neutral → Sell |
| Aug-08-25 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-13-25 | Downgrade | UBS | Buy → Neutral |
| Feb-12-25 | Initiated | Morgan Stanley | Underweight |
| Feb-04-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Dec-04-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Sep-11-24 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-05-24 | Downgrade | Goldman | Buy → Neutral |
| Sep-03-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-24 | Downgrade | Deutsche Bank | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-23-24 | Initiated | BMO Capital Markets | Market Perform |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-25-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-26-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-27-23 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-26-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-05-22 | Upgrade | Stifel | Hold → Buy |
| Sep-15-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| May-09-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-10-22 | Resumed | Citigroup | Buy |
| Dec-14-21 | Downgrade | Redburn | Buy → Neutral |
| Dec-06-21 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-03-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Sep-20-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-22-21 | Initiated | Bernstein | Mkt Perform |
| Mar-10-21 | Downgrade | Argus | Buy → Hold |
| Feb-01-21 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Sep-10-20 | Upgrade | UBS | Neutral → Buy |
| Sep-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-15-20 | Upgrade | Citigroup | Neutral → Buy |
| Mar-10-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-25-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-10-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-02-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Underperform → Buy |
| May-29-18 | Downgrade | HSBC Securities | Buy → Hold |
| May-25-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jan-25-18 | Reiterated | Leerink Partners | Outperform |
| Dec-06-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jul-26-17 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jul-05-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Mar-09-17 | Initiated | Liberum | Buy |
View All
Novartis Ag Adr Stock (NVS) Latest News
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy - Zacks Investment Research
Novartis AG Lobbying Profile, 2004 - OpenSecrets
Earnings Preview: Novartis AG to Report Financial Results on October 27 - Moomoo
Novartis (NVS) Gains European Commission Approval for Cosentyx i - GuruFocus
European Commission OKs Novartis' Cosentyx for Treatment of Polymyalgia Rheumatica - marketscreener.com
Novartis receives European Commission approval for Cosentyx(R) in polymyalgia rheumatica (PMR) - marketscreener.com
Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR) - GlobeNewswire
Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR) - Yahoo Finance
Novartis AG Bills, 2012 - OpenSecrets
Novartis ranks #19 in TIME and Statista’s World’s Best Companies 2026 - Novartis
Novartis AG : UBS gives a Neutral rating - marketscreener.com
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth - Zacks Investment Research
Novartis AG (NVS) Options ChainYahoo Finance - Yahoo! Finance Canada
Enterprise value to revenue forward of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVSC - TradingView
Novartis: The Sell-Off Creates An Attractive Entry Point (NYSE:NVS) - Seeking Alpha
Novartis Has Five Fast-Growing Drugs, but Is Its Valuation Asking Too Much? - Yahoo Finance
Novartis Discontinues Mid-Stage Fabhalta Trial in Lupus Nephritis for Strategic Reasons - Yahoo Finance
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition - Reuters
Novartis AG (NVSD.BA) valuation measures and financial statistics - Yahoo Finance Australia
Novartis AG (NOVN.VI) interactive stock chart - Yahoo Finance UK
Novartis AG (NVS) Stock forecasts - Yahoo Finance UK
RBC Capital Remains a Hold on Novartis AG (NOVN) - The Globe and Mail
Novartis AG (NVS) Stock Forecasts - Yahoo! Finance Canada
Novartis wins Rhapsido approval as Bank of America keeps CHF 150 target for Novartis stock - ad-hoc-news.de
Novartis AG : RBC is Neutral - www.marketscreener.com
IgA Nephropathy Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences - StreetInsider
Novartis AG Stock (NVS) Moved Up by 3.00% on Oct 15: Drivers Behind the Movement - TradingKey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AGNVS - PR Newswire
Novartis AG (NVS) Stock Forecasts - Yahoo Finance
Novartis AG (NOT.F) Analyst Insights, Price Targets & RecommendationsYahoo Finance - Yahoo! Finance Canada
Genentech Wins Judge's OK Of $18M Novartis Award - Law360
Novartis AG (NVS) Stock Up 3.1% but GF Value Says Overvalued -- GF Score: 68/100 - GuruFocus
US biotech company enforces eye treatment award against Novartis - Global Arbitration Review
Why Novartis (NVS) Stock Is Up Today - Quiver Quantitative
Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire Inc.
Law firm probes Novartis over possible securities fraud after trial failure drops shares 14%. - Pluang
Community health takes a village: Screening in the barber’s chair - Novartis
Novartis AG NVSEF Stock Forecast & Price Target - Yahoo! Finance Canada
NOVARTIS AG N (NOT.HA) Q2 FY2026 earnings call transcript - Yahoo Finance
Novartis AG Rises Monday - Moomoo
Swiss Blue-chip Index Starts Week Upbeat; Roche, Novartis Shares Gain - marketscreener.com
Weekly Recap: Abogen mRNA T‑cell engager investment and Rhapsido approval - TradingView
Novartis AG (CEUX:1NOVNm) Stock PDF (Updated: 2026/10/10) - GuruFocus
Cancer Stocks to Consider as Oncology Innovation Accelerates - Zacks Investment Research
Novartis AG (NOVN.VI) income statement - Yahoo Finance UK
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido - The Globe and Mail
Swiss Market Index Retreats; Novartis Shares Decline - marketscreener.com
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido - Zacks Investment Research
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AGNVS - PR Newswire
Novartis achieves Tier 1 in the 2026 CCLA Corporate Mental Health Benchmark - Novartis
Novartis Ag Adr Stock (NVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novartis Ag Adr Stock (NVS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Marshall Fiona | Officer |
Feb 12 '26 |
Proposed Sale |
161.35 |
30,743 |
4,960,277 |
0 |
| Bulto Carulla Victor | Officer |
Feb 09 '26 |
Proposed Sale |
156.21 |
7,500 |
1,171,576 |
0 |
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):